ENVALITH
アキレス株式会社 logo

Achilles Corporation

5142・Prime Market・Chemicals

Official website
アキレス株式会社 logo
Achilles Corporation5142

Business

Achilles Corporation is a plastics processing manufacturer founded in 1947, listed on the Prime Market of the Tokyo Stock Exchange. With 19 consolidated subsidiaries and 3 affiliated companies, the company reported net sales of ¥81,802 million (FY2026, ending March 2026). Its business is organized into three segments: the "First Business Division" (Film, Vehicle Materials, Urethane, Industrial Materials), the "Second Business Division" (Insulation Materials, Building & Interior Materials, Disaster Prevention Products), and "Shoes BU" (Shunsoku, Achilles Sorbo, BROOKS, and others). Major customers span a wide range of industries including automotive, semiconductors, medical devices, construction, and retail, and the company operates globally with overseas bases in the US, China, and Taiwan in addition to its domestic plants. Under its medium-term management plan (FY25–FY27), the company has set "Global Solution Provider" as its long-term goal, promoting selection and concentration in priority fields such as electronics, mobility, and medical.

Business Model

Centered on proprietary plastics processing technologies—compounding, film formation, foaming, insulation, and conductivity treatment—the company manufactures and sells a diverse range of products including vehicle interior materials, medical films, semiconductor transport components, insulation materials, and shoes. The First Business Division (Electronics, Medical, Mobility) accounts for approximately 61% of revenue, the Second Business Division (Building Materials, Disaster Prevention) approximately 28%, and the Shoes BU approximately 11%. The structure aims to improve profit margins through cost reduction via consolidated manufacturing at production sites and a product mix shift toward high-value-added fields.

Company Strengths

The company possesses proprietary plastic processing technologies such as film forming, foaming, and conductivity treatment, and develops high-value-added products including semiconductor wafer transport components, RIM-molded products for medical devices, and Film (for Medical & Electronics Applications). In FY2026 (ending March 2026), the First Business Division's segment profit increased 228.0% year-on-year to ¥3,287 million, demonstrating that technological capability translates directly into profitability.

In addition to multiple domestic plants (Ashikaga, Shiga, Bibai, Kyushu, etc.), the company has overseas bases in the United States, China (Shanghai, Foshan, Kunshan), and Taiwan. In FY2026 (ending March 2026), U.S. sales expanded from ¥8,018 million in the previous fiscal year to ¥10,390 million, with the global production and sales structure supporting growth in the North and Central American markets.

The "Shunsoku" brand held by the Shoes BU has surpassed cumulative series sales of 86 million pairs, giving it high brand recognition and strength in the domestic children's footwear market. The company also operates multiple other brands such as "Achilles Sorbo" and "BROOKS," giving it the capability to address the health-conscious market as well. Note that this segment faces structural headwinds such as the declining birthrate and weak department store sales, making the maintenance of brand strength a challenge.

ENVALITH's Perspective

Operating profit of ¥2,972 million in FY2026 (ending March 2025) [as stated] represents a dramatic improvement from the prior period's loss of ¥436 million, but this is mainly attributable to substantial growth in film for medical applications and the recognition of ¥693 million in foreign exchange gains. The FY2027 (ending March 2027) forecast anticipates ordinary profit of ¥2,000 million (down 49.0% year on year), a significant decline in profit, as the drop-off of foreign exchange gains and increased investment in human capital and DX are expected to weigh on earnings. The continuity of demand for film and industrial materials, together with the high degree of dependence on external factors (yen depreciation, semiconductor demand), will determine the sustainability of earnings.

In FY2026 (ending March 2026), an impairment loss of ¥905 million was recognized as an extraordinary loss on fixed assets related to the disaster prevention business. In the prior period (FY2025, ending March 2025), an impairment of ¥3,256 million was recognized, and two consecutive periods of impairment indicate delays in achieving the initial business plan. While segment profit for the Second Business Division as a whole improved to ¥2,390 million, the delay in monetizing the disaster prevention business raises questions about the effectiveness of the "selection and concentration" strategy under the medium-term management plan. The future direction of the disaster prevention business (continuation, downsizing, or withdrawal) will be a key point of attention going forward.

Shoes BU posted a significant decline in revenue to ¥8,928 million (down 11.7% year on year) due to the effects of the declining birthrate, weak department store sales, and price revisions, and continues to record a segment loss of ¥321 million. Vehicle materials have also continued to fall short of the prior year's results due to production cuts by Japanese automakers in China, with structural changes in the Chinese automotive market (the shift to EVs and to domestic brands) acting as an external headwind. The structure in which the earnings drag from these two businesses weighs down overall company profit may persist over the medium term, making it essential for the First Business Division to offset this through higher profitability.

Growth Strategy

Under the medium-term management plan for FY25–FY27, the company is pursuing three pillars: "selection and concentration," "new value creation," and "global strategy."

The company has positioned medical-use film and semiconductor-related industrial materials as top-priority fields, promoting expanded manufacturing capacity and deeper customer engagement. In FY2026 (ending March 2026), First Business Division segment profit expanded to ¥3,287 million (up 228.0% year on year), and continued growth is expected in FY2027 (ending March 2027) as well.

The company has positioned regional profitability management as a key management indicator, expanding U.S. sales in the First Business Division by 29.6% from ¥8,018 million in the prior period to ¥10,390 million in the current period. Business expansion in priority fields continues to be promoted, with a focus on the North/Central America region.

Active investment in human capital management and DX promotion, as set forth in the medium-term management plan, has already been incorporated into the FY2027 (ending March 2027) earnings forecast. This is one of the main factors behind the projected decline in operating profit for FY2027 (down 26.0% year on year), with the aim of improving productivity and competitiveness over the medium to long term.

Amid external headwinds such as the declining birthrate and sluggish consumer spending, the company improved segment loss by ¥651 million, from ¥972 million in the prior period to ¥321 million, through review of procurement costs, expense reductions, and price revisions. The company continues to aim for further loss reduction through ongoing cost-cutting activities and the introduction of new functional products.

The disaster prevention business has recorded impairment losses for two consecutive periods (¥3,256 million in FY2025 and ¥905 million in FY2026), highlighting delays in achieving profitability. While overall profit in the Second Business Division has improved due to price revisions in Insulation Materials and Building & Interior Materials and expansion into the non-residential field, a fundamental review of the direction of the disaster prevention business remains a challenge.

Last updated: July 19, 2026